J C Sinclair
Affiliation: McMaster University
- When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatmentJ C Sinclair
Department of Clinical Epidemiology and Biostatistics, McMaster University, Room 3N11F, 1200 Main Street West, Hamilton, L8N 3Z5, Ontario, Canada
J Clin Epidemiol 54:253-62. 2001..Quantification of the determinants of the threshold NNT and of the minimum event rate to justify treatment can assist clinicians and patients in the explicit use of underlying values when making treatment decisions...
- Weighing risks and benefits in treating the individual patientJohn C Sinclair
Department of Pediatrics, McMaster University, Room 3N11F, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
Clin Perinatol 30:251-68. 2003..Consideration of the determinants of the threshold NNT may assist clinicians and parents in the explicit use of underlying values when making treatment decisions...
- Longitudinal measurements of oxygen consumption in growing infants during the first weeks after birth: old data revisitedJ C Sinclair
Department of Pediatrics, McMaster University, Hamilton, Ont, Canada
Neonatology 103:224-32. 2013..In a study conducted in 1966-1969, longitudinal measurements were made of the metabolic rate in growing infants. Statistical methods for analyzing longitudinal data weren't readily accessible at that time...
- Selecting participants that raise a clinical trial's population attributable fraction can increase the treatment effect within the trial and reduce the required sample sizeJohn C Sinclair
Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada
J Clin Epidemiol 64:893-902. 2011..Detection of modest but worthwhile treatment effects in randomized controlled trials (RCTs) demands trials of large sample size. Approaches to decreasing required size of RCTs while maintaining power are needed...
- Evidence-based therapy in neonatology: distilling the evidence and applying it in practiceJ C Sinclair
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Acta Paediatr 93:1146-52. 2004....
- Cochrane neonatal systematic reviews: a survey of the evidence for neonatal therapiesJohn C Sinclair
Department of Pediatrics, McMaster University Medical Centre, Room 3N11F, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
Clin Perinatol 30:285-304. 2003..Most CNRG reviews were current. There is a continuing need to prepare systematic review of therapies not yet covered and to keep an increasing number of reviews up-to-date...
- Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based?Jeffrey D Horbar
Department of Pediatrics, University of Vermont College of Medicine, Burlington, Vermont, USA
Pediatrics 113:1593-602. 2004..To describe the timing of initial surfactant treatment for high-risk preterm infants in routine practice and compare these findings with evidence from randomized trials and published guidelines...
- The Nils Rosén von Rosenstein Award 2004G Sedin
Department of Women s and Children s Health, Section for Paediatrics, Perinatal Research Laboratory, Uppsala University Children s Hospital, Uppsala, Sweden
Acta Paediatr 93:1144-5. 2004
- Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trialJeffrey D Horbar
Vermont Oxford Network, 33 Kilburn Street, Burlington, VT 05401, USA
BMJ 329:1004. 2004..To test a multifaceted collaborative quality improvement intervention designed to promote evidence based surfactant treatment for preterm infants of 23-29 weeks' gestation...
- Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung diseaseLex W Doyle
Division of Paediatrics, Royal Women s Hospital, 132 Grattan St, Carlton 3053, Australia
Pediatrics 115:655-61. 2005..The objective of this study was to determine the effect of systemic postnatal corticosteroid treatment on death and CP and to assess any modification of effect arising from risk for CLD...